NasdaqCM - Nasdaq Real Time Price USD

Imunon, Inc. (IMNN)

1.2871 -0.0229 (-1.75%)
As of 11:39 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
500.0000
500.0000
500.0000
Operating Expense
20,357.4260
21,030.4300
25,421.5650
21,507.1900
18,986.4120
Operating Income
-20,357.4260
-21,030.4300
-24,921.5650
-21,007.1900
-18,486.4120
Net Non Operating Interest Income Expense
487.9620
528.7440
-4,526.0400
-551.7360
-1,225.7850
Other Income Expense
-264.0580
-293.6760
-8,017.6550
-593.7700
-3,617.1870
Pretax Income
-20,133.5220
-20,795.3620
-37,465.2600
-22,152.6960
-23,329.3840
Tax Provision
--
-1,280.3850
-1,567.0260
-1,383.4460
-1,845.8230
Net Income Common Stockholders
-18,853.1370
-19,514.9770
-35,898.2340
-20,769.2500
-21,483.5610
Diluted NI Available to Com Stockholders
-18,853.1370
-19,514.9770
-35,898.2340
-20,769.2500
-21,483.5610
Basic EPS
-2.00
-2.16
-5.03
-3.83
-10.08
Diluted EPS
-2.00
-2.16
-5.03
-3.83
-10.08
Basic Average Shares
9,324.9070
9,045.3200
7,142.9700
5,426.9530
2,129.6950
Diluted Average Shares
9,324.9070
9,045.3200
7,142.9700
5,426.9530
2,129.6950
Total Operating Income as Reported
-20,357.4260
-21,030.4300
-24,921.5650
-21,007.1900
-18,486.4120
Total Expenses
20,357.4260
21,030.4300
25,421.5650
21,507.1900
18,986.4120
Net Income from Continuing & Discontinued Operation
-18,853.1370
-19,514.9770
-35,898.2340
-20,769.2500
-21,483.5610
Normalized Income
-18,985.3980
-19,611.3588
-28,207.5757
-20,210.5125
-18,155.7425
Interest Income
525.0570
725.8240
502.5780
18.1450
66.5530
Interest Expense
37.0950
197.0800
5,028.6180
569.8810
1,292.3380
Net Interest Income
487.9620
528.7440
-4,526.0400
-551.7360
-1,225.7850
EBIT
-20,096.4270
-20,598.2820
-32,436.6420
-21,582.8150
-22,037.0460
EBITDA
-19,390.7900
-19,878.2770
-31,705.0130
-20,879.8970
-21,295.5220
Reconciled Depreciation
705.6370
720.0050
731.6290
702.9180
741.5240
Net Income from Continuing Operation Net Minority Interest
-18,853.1370
-19,514.9770
-35,898.2340
-20,769.2500
-21,483.5610
Total Unusual Items Excluding Goodwill
132.2610
102.6430
-8,019.4560
-595.6690
-3,617.1940
Total Unusual Items
132.2610
102.6430
-8,019.4560
-595.6690
-3,617.1940
Normalized EBITDA
-19,523.0510
-19,980.9200
-23,685.5570
-20,284.2280
-17,678.3280
Tax Rate for Calcs
--
0.0001
0.0000
0.0001
0.0001
Tax Effect of Unusual Items
--
6.2612
-328.7977
-36.9315
-289.3755
12/31/2020 - 3/1/1999

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

COEP Coeptis Therapeutics Holdings, Inc.
0.2699
+0.90%
 
DRMA Dermata Therapeutics, Inc.
3.7900
+8.60%
 
ALRN Aileron Therapeutics, Inc.
3.1650
-3.80%
 
AEZS Aeterna Zentaris Inc.
7.33
+0.96%
 
ANEB Anebulo Pharmaceuticals, Inc.
2.1650
-1.59%
 
XBIO Xenetic Biosciences, Inc.
3.9800
-1.97%
 
LSTA Lisata Therapeutics, Inc.
3.2300
+3.19%
 
BTTX Better Therapeutics, Inc.
0.0125
+31.58%
 
SIGHT.PA GenSight Biologics S.A.
0.3700
-2.25%
 
OCEAW Ocean Biomedical, Inc.
0.0450
-25.00%